Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis
Details : CLS12311 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Multiple Sclerosis, Relapsing-Remitting.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 28, 2024
Lead Product(s) : CLS12311
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Collaboration
Novartis Signs Deal that Could Lead to Acquisition of Zurich Start-Up Cellerys
Details : Zurich-based Cellerys is working on new multiple sclerosis drug, CLS12311, which is currently in phase 2. Novartis is pairing up with the biotech on the asset but nabs the option to acquire Cellerys upon completion of a phase 2 trial in the coming years.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
June 01, 2021
Lead Product(s) : CLS12311
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
